The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates

A Harrison; C A Walker; D Parker; K J Jankowski; J P Cox; A S Craig; J M Sansom; N R Beeley; R A Boyce; L Chaplin

doi:10.1016/0883-2897(91)90107-v

The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates

Int J Rad Appl Instrum B. 1991;18(5):469-76. doi: 10.1016/0883-2897(91)90107-v.

Authors

A Harrison¹, C A Walker, D Parker, K J Jankowski, J P Cox, A S Craig, J M Sansom, N R Beeley, R A Boyce, L Chaplin, et al.

Affiliation

¹ MRC Radiobiology Unit, Chilton, Didcot, Oxon, England.

PMID: 1917516
DOI: 10.1016/0883-2897(91)90107-v

Abstract

Yttrium binding ligands DOTA, caDTPA and CT-DTPA were each conjugated to monoclonal antibody B72.3, labelled with 90Y and injected into mice in order to assess the in vivo inertness of the antibody-linked 90Y-ligand complexes. Levels of 90Y in femur shafts of the DOTA-B72.3 mice were low, being approximately 7 and 44%, respectively, of levels in the femur shafts of the caDTPA-B72.3 and CT-DTPA-B72.3 treated mice. This finding demonstrates the greater inertness and by implication the greater suitability for immunotherapy of the DOTA-90Y complex.

MeSH terms

Animals
Antibodies, Monoclonal* / chemistry
Bone Marrow / metabolism
Bone and Bones / metabolism
Heterocyclic Compounds / pharmacokinetics
Heterocyclic Compounds, 1-Ring*
Immunoglobulin G / immunology
Isotope Labeling
Ligands
Male
Mice
Mice, Inbred Strains
Pentetic Acid / chemistry
Yttrium Radioisotopes / pharmacokinetics*

Substances

Antibodies, Monoclonal
Heterocyclic Compounds
Heterocyclic Compounds, 1-Ring
Immunoglobulin G
Ligands
Yttrium Radioisotopes
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Pentetic Acid